Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31366629 | 1.00 | ADRA1A (0.54) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL25409835 | 1.00 | ADRA1A (0.54) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL21272249 | 0.88 | CHRM1 (0.58) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL21272128 | 0.88 | CHRM1 (0.58) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL31366513 | 0.85 | GABRA1 (0.71) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25412361 | 0.85 | GABRA1 (0.71) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25412359 | 0.85 | GABRA1 (0.71) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3142613 | 0.85 | GABRA1 (0.70) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7722823 | 0.85 | GABRA1 (0.70) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL28926380 | 0.84 | ADRA1A (0.53) | ADRA1AGABRA1GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE | 2025-06-19 | — | — | US | disclosed |
| WO-2023172726-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | CUL4B, BRD4, CUL4A | ADRA1A 3323/4885GABRA1 2493/4885GABRA5 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.